Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) – Equities researchers at Jefferies Group issued their Q1 2017 earnings estimates for Dicerna Pharmaceuticals in a research report issued to clients and investors on Monday. Jefferies Group analyst E. Yang expects that the firm will post earnings per share of ($0.73) for the quarter. Jefferies Group also issued estimates for Dicerna Pharmaceuticals’ Q2 2017 earnings at ($0.73) EPS, Q3 2017 earnings at ($0.50) EPS and Q4 2017 earnings at ($0.50) EPS.

A number of other research analysts have also issued reports on DRNA. Leerink Swann reiterated a “buy” rating and set a $8.00 price target on shares of Dicerna Pharmaceuticals in a research report on Tuesday. Zacks Investment Research lowered Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 5th. Chardan Capital reduced their price target on Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating for the company in a research report on Monday, August 8th. Cowen and Company reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Friday, August 5th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $13.00 price target on shares of Dicerna Pharmaceuticals in a research report on Wednesday, September 28th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $9.85.

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at 3.20 on Wednesday. The firm’s 50-day moving average is $4.13 and its 200 day moving average is $3.67. The firm’s market cap is $66.41 million. Dicerna Pharmaceuticals has a 52 week low of $2.69 and a 52 week high of $15.93.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.17. The business had revenue of $162 million for the quarter.

Hedge funds have recently bought and sold shares of the company. Oxford Asset Management increased its stake in Dicerna Pharmaceuticals by 109.3% in the second quarter. Oxford Asset Management now owns 286,413 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 149,560 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Dicerna Pharmaceuticals during the first quarter worth about $343,000. Northern Trust Corp raised its stake in shares of Dicerna Pharmaceuticals by 19.6% in the third quarter. Northern Trust Corp now owns 43,612 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 7,149 shares during the period. Paloma Partners Management Co bought a new stake in shares of Dicerna Pharmaceuticals during the second quarter worth about $183,000. Finally, A.R.T. Advisors LLC bought a new stake in shares of Dicerna Pharmaceuticals during the second quarter worth about $170,000. 62.37% of the stock is currently owned by institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

5 Day Chart for NASDAQ:DRNA

Receive News & Stock Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.